AAPL325.89-1.85 (-0.56%) ▼|ABBV253.30-2.80 (-1.09%) ▼|ABT100.57+0.90 (+0.90%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|AAPL325.89-1.85 (-0.56%) ▼|ABBV253.30-2.80 (-1.09%) ▼|ABT100.57+0.90 (+0.90%) ▲|ACN140.09-0.77 (-0.55%) ▼|ADBE218.36-8.80 (-3.87%) ▼|AMAT553.92-10.63 (-1.88%) ▼|AMD552.33+7.90 (+1.45%) ▲|AMGN366.05-0.19 (-0.05%) ▼|AMT166.06+2.67 (+1.63%) ▲|AMZN244.85-2.70 (-1.09%) ▼|AVGO396.81+10.31 (+2.67%) ▲|AXP348.74-2.05 (-0.58%) ▼|BA208.65+3.85 (+1.88%) ▲|BAC61.62+0.40 (+0.65%) ▲|BKNG177.86-1.54 (-0.86%) ▼|BLK1,056.63+18.39 (+1.77%) ▲|BMY60.76-0.17 (-0.28%) ▼|BNY160.39+1.50 (+0.94%) ▲|BRK-B489.39-0.26 (-0.05%) ▼|C132.25-0.59 (-0.44%) ▼|CAT889.31-0.66 (-0.07%) ▼|CL91.63+1.13 (+1.25%) ▲|CMCSA23.52-0.29 (-1.22%) ▼|COF201.36-4.86 (-2.36%) ▼|COP118.79+1.29 (+1.10%) ▲|COST927.31-1.91 (-0.21%) ▼|CRM163.00-7.06 (-4.15%) ▼|CSCO112.21+0.03 (+0.03%) ▲|CVS108.08-2.52 (-2.28%) ▼|CVX192.98+1.91 (+1.00%) ▲|DE607.33+20.45 (+3.48%) ▲|DHR179.14+0.13 (+0.07%) ▲|DIS95.87-0.27 (-0.28%) ▼|DUK127.95+2.04 (+1.62%) ▲|EMR139.63+0.37 (+0.27%) ▲|FDX321.02+5.83 (+1.85%) ▲|GD373.16+5.43 (+1.48%) ▲|GE341.19+0.49 (+0.14%) ▲|GEV985.03-93.78 (-8.69%) ▼|GILD130.34+0.06 (+0.05%) ▲|GM82.13+2.61 (+3.28%) ▲|GOOG341.91-4.28 (-1.24%) ▼|GOOGL342.09-5.06 (-1.46%) ▼|GS1,098.20+12.64 (+1.16%) ▲|HD331.45-0.15 (-0.05%) ▼|HON232.99+3.13 (+1.36%) ▲|IBM205.77-4.73 (-2.25%) ▼|INTC102.62-2.83 (-2.68%) ▼|INTU284.47-5.45 (-1.88%) ▼|ISRG340.69-9.37 (-2.68%) ▼|JNJ255.63+5.02 (+2.00%) ▲|JPM348.21+2.98 (+0.86%) ▲|KO82.20+0.23 (+0.28%) ▲|LIN508.67+3.64 (+0.72%) ▲|LLY1,163.01-12.40 (-1.06%) ▼|LMT514.36+7.27 (+1.43%) ▲|LOW204.35+2.09 (+1.03%) ▲|LRCX319.29-2.71 (-0.84%) ▼|MA531.98-6.32 (-1.17%) ▼|MCD263.57-0.34 (-0.13%) ▼|MDLZ60.86+1.00 (+1.67%) ▲|MDT81.89-0.46 (-0.56%) ▼|META627.17-16.64 (-2.58%) ▼|MMM170.76+0.00 (+0.00%) ▲|MO72.17-0.82 (-1.12%) ▼|MRK127.47+1.21 (+0.96%) ▲|MS218.50+2.10 (+0.97%) ▲|MSFT390.34-7.41 (-1.86%) ▼|MU959.48-11.34 (-1.17%) ▼|NEE89.41+1.48 (+1.68%) ▲|NFLX68.53-0.14 (-0.20%) ▼|NKE42.21-0.75 (-1.75%) ▼|NOW95.46-6.60 (-6.47%) ▼|NVDA212.06+4.77 (+2.30%) ▲|ORCL125.84-1.21 (-0.95%) ▼|PEP135.65+0.65 (+0.48%) ▲|PFE24.82-0.12 (-0.48%) ▼|PG149.13+1.03 (+0.70%) ▲|PLTR124.57-8.09 (-6.10%) ▼|PM194.30+6.26 (+3.33%) ▲|QCOM175.63+2.13 (+1.23%) ▲|RTX194.88+1.21 (+0.62%) ▲|SBUX103.98-0.47 (-0.45%) ▼|SCHW100.80+0.84 (+0.84%) ▲|SO95.80+1.95 (+2.08%) ▲|SPG226.22-0.57 (-0.25%) ▼|T23.04+0.78 (+3.50%) ▲|TMO526.46+3.00 (+0.57%) ▲|TMUS190.94+0.17 (+0.09%) ▲|TSLA374.01-4.92 (-1.30%) ▼|TXN294.19+2.89 (+0.99%) ▲|UBER70.33-1.22 (-1.71%) ▼|UNH431.31-5.04 (-1.16%) ▼|UNP292.56-0.57 (-0.19%) ▼|UPS115.84-0.50 (-0.43%) ▼|USB64.47+0.76 (+1.19%) ▲|V353.42-2.40 (-0.67%) ▼|VZ44.29+0.51 (+1.16%) ▲|WFC86.42-1.32 (-1.50%) ▼|WMT109.33-1.06 (-0.96%) ▼|XOM154.45+2.74 (+1.81%) ▲|
24.9 C
New York
Thursday, July 23, 2026

Tag: stiffness

newssourceFORcompanyinformationcontent1releasesmarket

PEEK Market worth $2.29 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 19, 2026 /PRNewswire/ -- According to MarketsandMarkets, 'PEEK Market by Reinforcement Type (Glass Filled, Carbon Filled, Unfilled), Processing Method (Extrusion, Injection...

PEEK Market worth $2.29 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 19, 2026 /PRNewswire/ -- According to MarketsandMarkets, 'PEEK Market by Reinforcement Type (Glass Filled, Carbon Filled, Unfilled), Processing Method (Extrusion, Injection...

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

New Case Series on Umbilical Tissue in Plantar Fascia Applications Demonstrates Clinical Reproducibility

Case Series by Dr. Robert Parker, DPM, Published in Archives of Clinical...

Antaisolar Showcases Upgraded 2P Tracker Solution at SNEC 2026, Securing Multiple Global Partnerships

XIAMEN, China, June 9, 2026 /PRNewswire/ -- Fresh from being ranked No.7 in Wood Mackenzie's 2026 global PV tracker TOP10 and named a Global A-Class...

Baycrest Research Highlights Overlooked Condition Affecting People with Advanced Dementia

New Publications Advance Understanding of Paratonia and Support More Compassionate CareTORONTO, June 8, 2026 /PRNewswire/ - Baycrest researchers and clinicians have contributed to newly...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

HighlightsFGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO® Material Solutions, Inc.Strategic acquisition expands FGR's...

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

HighlightsFGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO® Material Solutions, Inc.Strategic acquisition expands FGR's...

FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions

HighlightsFGR enters binding agreement to acquire all assets, intellectual property, product lines and manufacturing capabilities of USA-based MITO® Material Solutions, Inc.Strategic acquisition expands FGR's...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStiffness

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers